EPS Bio Technology Corp.
EPS Bio Technology Corp. manufactures and sells OEM/ODM blood glucose system in Taiwan. It also provides test strip; diabetic self-monitoring blood glucose systems under the EASYMAX and MDT2 BLE name; and wearable, and NFC and Bluetooth connectivity blood glucose monitors. The company was founded in 2006 and is headquartered in Hsinchu City, Taiwan.
EPS Bio Technology Corp. (4183) - Net Assets
Latest net assets as of December 2024: NT$304.55 Million TWD
Based on the latest financial reports, EPS Bio Technology Corp. (4183) has net assets worth NT$304.55 Million TWD as of December 2024.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (NT$541.89 Million) and total liabilities (NT$237.34 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | NT$304.55 Million |
| % of Total Assets | 56.2% |
| Annual Growth Rate | 0.7% |
| 5-Year Change | -1.49% |
| 10-Year Change | N/A |
| Growth Volatility | 2.96 |
EPS Bio Technology Corp. - Net Assets Trend (2019–2024)
This chart illustrates how EPS Bio Technology Corp.'s net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for EPS Bio Technology Corp. (2019–2024)
The table below shows the annual net assets of EPS Bio Technology Corp. from 2019 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | NT$304.55 Million | -0.49% |
| 2023-12-31 | NT$306.04 Million | -0.75% |
| 2022-12-31 | NT$308.36 Million | +3.03% |
| 2021-12-31 | NT$299.27 Million | -3.20% |
| 2020-12-31 | NT$309.15 Million | +5.13% |
| 2019-12-31 | NT$294.07 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to EPS Bio Technology Corp.'s total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 5.7% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | NT$17.70 Million | 5.81% |
| Common Stock | NT$238.00 Million | 78.15% |
| Other Components | NT$48.85 Million | 16.04% |
| Total Equity | NT$304.55 Million | 100.00% |
EPS Bio Technology Corp. Competitors by Market Cap
The table below lists competitors of EPS Bio Technology Corp. ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Carolina Rush Corporation
V:RUSH
|
$4.27 Million |
|
MainStreetChamber Holdings Inc.
PINK:MSCH
|
$4.27 Million |
|
Kumpulan H & L High-Tech Bhd
KLSE:7033
|
$4.27 Million |
|
RPCG PCL -NVDR- BA 1
F:W8M1
|
$4.27 Million |
|
Living Cell Technologies Limited
PINK:LVCLF
|
$4.27 Million |
|
Fresh Grapes LLC
NYSE MKT:VINE
|
$4.27 Million |
|
MOODY'S
BE:DUT
|
$4.27 Million |
|
AB Panevezio Statybos Trestas
STU:YK3
|
$4.27 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in EPS Bio Technology Corp.'s equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 306,039,000 to 304,552,000, a change of -1,487,000 (-0.5%).
- Net income of 17,307,000 contributed positively to equity growth.
- Dividend payments of 19,040,000 reduced retained earnings.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | NT$17.31 Million | +5.68% |
| Dividends Paid | NT$19.04 Million | -6.25% |
| Other Changes | NT$246.00K | +0.08% |
| Total Change | NT$- | -0.49% |
Book Value vs Market Value Analysis
This analysis compares EPS Bio Technology Corp.'s book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.25x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2019-12-31 | NT$12.31 | NT$16.00 | x |
| 2020-12-31 | NT$12.92 | NT$16.00 | x |
| 2021-12-31 | NT$12.53 | NT$16.00 | x |
| 2022-12-31 | NT$12.92 | NT$16.00 | x |
| 2023-12-31 | NT$12.82 | NT$16.00 | x |
| 2024-12-31 | NT$12.76 | NT$16.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently EPS Bio Technology Corp. utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 5.68%
- The company has moderate efficiency in generating returns from equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 3.84%
- • Asset Turnover: 0.83x
- • Equity Multiplier: 1.78x
- Recent ROE (5.68%) is below the historical average (7.25%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2019 | 6.27% | 4.01% | 0.86x | 1.82x | NT$-10.97 Million |
| 2020 | 10.25% | 6.64% | 0.87x | 1.77x | NT$785.60K |
| 2021 | 6.23% | 3.88% | 0.83x | 1.93x | NT$-11.29 Million |
| 2022 | 8.22% | 5.47% | 0.88x | 1.71x | NT$-5.48 Million |
| 2023 | 6.86% | 4.46% | 0.87x | 1.77x | NT$-9.61 Million |
| 2024 | 5.68% | 3.84% | 0.83x | 1.78x | NT$-13.15 Million |
Industry Comparison
This section compares EPS Bio Technology Corp.'s net assets metrics with peer companies in the Medical Devices industry.
Industry Context
- Industry: Medical Devices
- Average net assets among peers: $1,286,393,556
- Average return on equity (ROE) among peers: 10.58%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| EPS Bio Technology Corp. (4183) | NT$304.55 Million | 6.27% | 0.78x | $4.27 Million |
| Health & Life Co., Ltd. (1781) | $393.05 Million | 6.17% | 1.08x | $12.92 Million |
| Hi-Clearance (1788) | $3.00 Billion | 11.98% | 0.65x | $104.25 Million |
| Radiant Innovation (3373) | $865.89 Million | -3.30% | 0.08x | $18.76 Million |
| Wellell Inc (4106) | $458.47 Million | 22.17% | 0.32x | $37.12 Million |
| Rossmax International Ltd (4121) | $1.66 Billion | 8.16% | 1.02x | $34.41 Million |
| United Orthopedic (4129) | $2.22 Billion | 5.87% | 0.94x | $279.97 Million |
| Dynamic Medical Technologies (4138) | $1.70 Billion | 12.34% | 0.81x | $39.16 Million |
| Ok Biotech Co Ltd (4155) | $452.10 Million | 21.38% | 0.72x | $44.61 Million |
| Bioptik Technology (4161) | $824.15 Million | 10.40% | 0.82x | $30.48 Million |